参考文献/References:
[1] Schechter AL, Stern DF, Vaidyanathan L, et al.The neu oncogene:an erb-B-related gene encoding a 185, 000-Mr tumour antigen[J].Nature, 1984, 312(5994):513-516.
[2] Siegel R, Naishadham D, Jemal A.Cancer statistics, 2013[J].CA Cancer J Clin, 2013, 63(1):11-30.DOI:10.3322/caac.21166.
[3] 刘芳, 唐光才.乳腺癌影像诊断的研究现状[J].国际医学放射学杂志, 2013, 36(6):533-537.DOI:10.3874/j.issn.1674-1897.2013.06.Z0605.Liu F, Tang GC.The current status of imaging diagnosis of breast cancer[J].Int J Med Radiol, 2013, 36(6):533-537.
[4] King CR, Kraus MH, Aaronson SA.Amplification of a novel v-erbB-related gene in a human mammary carcinoma[J].Science, 1985, 229(4717):974-976.DOI:10.1126/science.2992089.
[5] Slamon DJ, Clark GM, Wong SG, et al.Human breast cancer:correlation of relapse and survival with amplification of the HER-2/neu oncogene[J].Science, 1987, 235(4785):177-182.DOI:10.1126/science.3798106.
[6] Ross JS, Slodkowska EA, Symmans WF, et al.The HER-2 receptor and breast cancer:ten years of targeted anti-HER-2 therapy and personalized medicine[J].Oncologist, 2009, 14(4):320-368.DOI:10.1634/theoncologist.2008-0230.
[7] Fu W, Lobocki CA, Silberberg BK, et al.Molecular markers in Paget disease of the breast[J].J Surg Oncol, 2001, 77(3):171-178.DOI:10.1002/jso.1090.
[8] Debska-Szmich S, Krakowska M, Czernek U, et al.The role of preoperative systemic treatment in patients with breast cancer[J].Contemp Oncol(Pozn), 2016, 20(2):93-101.DOI:10.5114/wo.2016.60067.
[9] Zhang B, Cai FF, Zhong XY.An overview of biomarkers for the ovarian cancer diagnosis[J].Eur J Obstet Gynecol Reprod Biol, 2011, 158(2):119-123.DOI:10.1016/j.ejogrb.2011.04.023.
[10] Corney DC, Hwang CI, Matoso A, et al.Frequent downregulation of miR-34 family in human ovarian cancers[J].Clin Cancer Res, 2010, 16(4):1119-1128.DOI:10.1158/1078-0432.CCR-09-2642.
[11] Verri E, Guglielmini P, Puntoni M, et al.HER2/neu oncoprotein overexpression in epithelial ovarian cancer:evaluation of its prevalence and prognostic significance.Clinical study[J].Oncology, 2005, 68(2/3):154-161.DOI:10.1159/000086958.
[12] Tanabe H, Nishii H, Sakata A, et al.Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma[J].Gynecol Oncol, 2004, 94(3):735-739.DOI:10.1016/j.ygyno.2004.05.055.
[13] Mano MS, Awada A, Di LA, et al.Rates of topoisomerase Ⅱ-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma[J].Gynecol Oncol, 2004, 92(3):887-895.DOI:10.1016/j.ygyno.2003.12.010.
[14] Bookman MA, Darcy KM, Clarke-Pearson D, et al.Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2:a phase Ⅱ trial of the Gynecologic Oncology Group[J].J Clin Oncol, 2003, 21(2):283-290.DOI:10.1200/JCO.2003.10.104.
[15] Tuefferd M, Couturier J, Penault-Llorca F, et al.HER2 status in ovarian carcinomas:a multicenter GINECO study of 320 patients[J/OL].PLoS One, 2007, 2(11):1138[2016-08-03].http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001138.DOI:10.1371/journal.pone.0001138.
[16] Suo Z, Karbovo E, Karbove K, et al.Papillary serous carcinoma of the ovary:an ultrastructural and immunohistochemical study[J].Ultrastruct Pathol, 2004, 28(3):141-147.DOI:10.1080/01913120490475716.
[17] O’Neill CJ, Deavers MT, Malpica A, et al.An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas:significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms[J].Am J Surg Pathol, 2005, 29(8):1034-1041.
[18] Wang D, Zhu H, Ye Q, et al.Prognostic Value of KIF2A and HER2-Neu Overexpression in Patients with Epithelial Ovarian Cancer[J/OL].Medicine(Baltimore), 2016, 95(8):2803[2016-08-03].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779007/.DOI:10.1097/MD.0000000000002803.
[19] Chen WQ, Zheng RS, Zhang SW, et al.Annual report on status of cancer in China, 2010[J].Chin J Cancer Res, 2014, 26(1):48-58.DOI:10.3978/j.issn.1000-9604.2014.01.08.
[20] Abraháo-Machado LF, Jácome AA, Wohnrath DR, et al.HER2 in gastric cancer:comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays[J].World J Gastroenterol, 2013, 19(38):6438-6446.DOI:10.3748/wjg.v19.i38.6438.
[21] Bang YJ, Van Cutsem E, Feyereislova A, et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3, open-label, randomised controlled trial[J].Lancet, 2010, 376(9742):687-697.DOI:10.1016/S0140-6736(10)61121-X.
[22] Liang JW, Zhang JJ, Zhang T, et al.Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer:a meta-analysis of the literature[J].Tumour Biol, 2014, 35(5):4849-4858.DOI:10.1007/s13277-014-1636-3.
[23] Moelans CB, Milne AN, Morsink FH, et al.Low frequency of HER2 amplification and overexpression in early onset gastric cancer[J].Cell Oncol(Dordr), 2011, 34(2):89-95.DOI:10.1007/s13402-011-0021-0.
[24] Chen C, Yang JM, Hu TT, et al.Prognostic role of human epidermal growth factor receptor in gastric cancer:a systematic review and meta-analysis[J].Arch Med Res, 2013, 44(5):380-389.DOI:10.1016/j.arcmed.2013.07.001.
[25] Fisher SB, Fisher KE, Squires MH 3rd, et al.HER2 in resected gastric cancer:Is there prognostic value?[J].J Surg Oncol, 2014, 109(2):61-66.DOI:10.1002/jso.23456.
[26] Shen GS, Zhao JD, Zhao JH, et al.Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection:A large-scale multicenter study in China[J].World J Gastroenterol, 2016, 22(23):5406-5414.DOI:10.3748/wjg.v22.i23.5406.
[27] 任新瑜, 尹玉峰, 高洁, 等.中国人群胰腺癌与胃癌HER2/neu基因表达[J].协和医学杂志, 2012, 3(1):21-25.DOI:10.3969/j.issn.1674-9081.2012.01.006.Ren XY, Yin YF, Gao J, et al.Detection of HER2/neu Gene in Pancreatic and Gastric Adenocarcinoma among Chinese Patients[J].Med J Peking Union Med Coll Hosp, 2012, 3(1):21-25.
[28] Aumayr K, Soleiman A, Sahora K, et al.HER2 gene amplification and protein expression in pancreatic ductal adenocarcinomas[J].Appl Immunohistochem Mol Morphol, 2014, 22(2):146-152.DOI:10.1097/PAI.0b013e31828dc392.
[29] Ata A, Polat A, Serins?z E, et al.Prognostic value of increased HER2 expression in cancers of pancreas and biliary tree[J].Pathol Oncol Res, 2015, 21(3):831-838.DOI:10.1007/s12253-014-9847-x.
[30] Liu HL, Gandour-Edwards R, Lara PN, et al.Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization[J].Cancer J, 2001, 7(5):395-403.
[31] Ross JS, Sheehan CE, Hayner-Buchan AM, et al.Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma[J].Cancer, 1997, 79(11):2162-2170.DOI:10.1002/(SICI)1097-0142(19970601)79:11<2162:AID-CNCR14>3.0.CO;2-U.
[32] Signoretti S, Montironi R, Manola J, et al.Her-2-neu expression and progression toward androgen independence in human prostate cancer[J].J Natl Cancer Inst, 2000, 92(23):1918-1925.DOI:10.1093/jnci/92.23.1918.
[33] Andersson J, Rosestedt M, Orlova A.Imaging of HER2 may improve the outcome of external irradiation therapy for prostate cancer patients[J].Oncol Lett, 2015, 9(2):950-954.DOI:10.3892/ol.2014.2760.
[34] 邓在春, 俞文英, 胡国平, 等.erbB1/HER1和erbB2/HER2在肺癌的表达[J].现代实用医学, 2001, 13(11):539-541.DOI:10.3969/j.issn.1671-0800.2001.11.003.Deng ZC, Yu WY, Hu GP, et al.Expression of erbB1/HER1 and erbB2/HER2 in hung cancer[J].Modern Pract Med, 2001, 13(11):539-541.
[35] Shen H, Du G, Liu Z, et al.Assessment and prognostic analysis of EGFR mutations or/and HER2 overexpression in Uygur’s Non-small Cell Lung Cancer[J].Int J Clin Exp Med, 2015, 8(12):22300-22309.
[36] Han Y, Xu JM, Duan HQ, et al.Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib[J].Chin J Cancer, 2010, 29(1):69-75.
[37] Dijkers EC, Kosterink JG, Rademaker AP, et al.Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging[J].J Nucl Med, 2009, 50(6):974-981.DOI:10.2967/jnumed.108.060392.
[38] Oude Munnink TH, Korte MA, Nagengast WB, et al.89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft[J].Eur J Cancer, 2010, 46(3):678-684.DOI:10.1016/j.ejca.2009.12.009.
[39] Lub-de Hooge MN, Kosterink JG, Perik PJ, et al.Preclinical characterisation of 111In-DTPA-trastuzumab[J].Br J Pharmacol, 2004, 143(1):99-106.DOI:10.1038/sj.bjp.0705915.
[40] N Tinianow J, Pandya DN, Pailloux SL, et al.Evaluation of a 3-hydroxypyridin-2-one(2, 3-HOPO) Based Macrocyclic Chelator for 89Zr(4+) and Its Use for ImmunoPET Imaging of HER2 Positive Model of Ovarian Carcinoma in Mice[J].Theranostics, 2016, 6(4):511-521.DOI:10.7150/thno.14261.
[41] Smith-Jones PM, Solit DB, Akhurst T, et al.Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors[J].Nat Biotechnol, 2004, 22(6):701-706.DOI:10.1038/nbt968.
[42] Smith-Jones PM, Solit D, Afroze F, et al.Early tumor response to Hsp90 therapy using HER2 PET:comparison with 18F-FDG PET[J].J Nucl Med, 2006, 47(5):793-796.
[43] Dennis MS, Jin H, Dugger D, et al.Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent[J].Cancer Res, 2007, 67(1):54-261.DOI:10.1158/0008-5472.CAN-06-2531.
[44] Orlova A, Tolmachev V, Pehrson R, et al.Synthetic affibody molecules:a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors[J].Cancer Res, 2007, 67(5):2178-2186.DOI:10.1158/0008-5472.CAN-06-2887.
[45] Kramer-Marek G, Kiesewetter DO, Capala J.Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and 18F-labeled affibody molecules[J].J Nucl Med, 2009, 50(7):1131-1139.DOI:10.2967/jnumed.108.057695.
[46] Ahlgren S, W?llberg H, Tran TA, et al.Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine[J].J Nucl Med, 2009, 50(5):781-789.DOI:10.2967/jnumed.108.056929.
[47] Orlova A, W?llberg H, Stone-Elander S, et al.On the selection of a tracer for PET imaging of HER2-expressing tumors:direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model[J].J Nucl Med, 2009, 50(3):417-425.DOI:10.2967/jnumed.108.057919.
[48] S?rensen J, Sandberg D, Sandstr?m M, et al.First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule[J].J Nucl Med, 2014, 55(5):730-735.DOI:10.2967/jnumed.113.131243.
[49] S?rensen J, Velikyan I, Sandberg D, et al.Measuring HER2-receptor Expression In Metastatic Breast Cancer Using[68Ga]ABY-025 Affibody PET/CT[J].Theranostics, 2016, 6(2):262-271.DOI:10.7150/thno.13502.
[50] Westerlund K, Honarvar H, Norrstr?m E, et al.Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules[J].Mol Pharm, 2016, 13(5):1668-1678.DOI:10.1021/acs.molpharmaceut.6b00089.
[51] 蔡炯, 党永红, 郑堃, 等.含末端半胱氨酸人表皮生长因子受体2亲和体的68Ga标记和显像[J].中华核医学与分子影像杂志, 2013, 33(6):460-463.DOI:10.3760/cma.j.issn.2095-2848.2013.06.014.Cai J, Dang YH, Zheng K, et al.68Ga-labeled HER2 affibody with C-terminal cysteine and its PET imaging[J].Chin J Nucl Med Mol Imaging, 2013, 33(6):460-463.
[52] Honarvar H, Westerlund K, Altai M, et al.Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors[J].Theranostics, 2016, 6(1):93-103.DOI:10.7150/thno.12766.
[53] Strand J, Nordeman P, Honarvar H, et al.Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethyl-maleimide Decreases Renal Uptake of radioactivity[J].Chemistry-Open, 2015, 4(2):174-182.DOI:10.1002/open.201402097.
[54] Miller J, Doss M, McQuillen R, et al.Impact of expression system on the function of the C6.5 diabody PET radiotracer[J].Tumour Biol, 2012, 33(3):617-627.DOI:10.1007/s13277-012-0361-z.
[55] Robinson MK, Doss M, Shaller C, et al.Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody[J].Cancer Res, 2005, 65(4):1471-1478.DOI:10.1158/0008-5472.CAN-04-2008.
[56] Reddy S, Shaller CC, Doss M, et al.Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment[J].Clin Cancer Res, 2011, 17(6):1509-1520.DOI:10.1158/1078-0432.CCR-10-1654.
[57] Sedgwick SG, Smerdon SJ.The ankyrin repeat:a diversity of interactions on a common structural framework[J].Trends Biochem Sci, 1999, 24(8):311-316.
[58] Zahnd C, Kawe M, Stumpp MT, et al.Efficient tumor targeting with high-affinity designed ankyrin repeat proteins:effects of affinity and molecular size[J].Cancer Res, 2010, 70(4):1595-1605.DOI:10.1158/0008-5472.CAN-09-2724.
[59] Goldstein R, Sosabowski J, Livanos M, et al.Development of the designed ankyrin repeat protein(DARPin) G3 for HER2 molecular imaging[J].Eur J Nucl Med Mol Imaging, 2015, 42(2):288-301.DOI:10.1007/s00259-014-2940-2.
[60] Mironova KE, Chernykh ON, Ryabova AV, et al.Highly specific hybrid protein DARPin-mCherry for fluorescent visualization of cells overexpressing tumor marker HER2/neu[J].Biochemistry(Mosc), 2014, 79(12):1391-1396.DOI:10.1134/S0006297914120141.
[61] Hamers-Casterman C, Atarhouch T, Muyldermans S, et al.Naturally occurring antibodies devoid of light chains[J].Nature, 1993, 363(6428):446-448.DOI:10.1038/363446a0.
[62] Vaneycken I, Devoogdt N, Van Gassen N, et al.Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer[J].FASEB J, 2011, 25(7):2433-2446.DOI:10.1096/fj.10-180331.
[63] D’Huyvetter M, Aerts A, Xavier C, et al.Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer:evaluation of different bifunctional chelators[J].Contrast Media Mol Imaging, 2012, 7(2):254-264.DOI:10.1002/cmmi.491.
[64] Xavier C, Blykers A, Vaneycken I, et al.18F-nanobody for PET imaging of HER2 overexpressing tumors[J].Nucl Med Biol, 2016, 43(4):247-252.DOI:10.1016/j.nucmedbio.2016.01.002.
[65] Vaidyanathan G, McDougald D, Choi J, et al.Preclinical evaluation of 18F-labeled anti-HER2 nanobody conjugates for imaging HER2 receptor expression by immuno-PET[J].J Nucl Med, 2016, 57(6):967-973.DOI:10.2967/jnumed.115.171306.
[66] Massa S, Vikani N, Betti C, et al.Sortase A-mediated site-specific labeling of camelid single-domain antibody-fragments:a versatile strategy for multiple molecular imaging modalities[J/OL].Contrast Media Mol Imaging, 2016[2016-08-03].http://onlinelibrary.wiley.com/doi/10.1002/cmmi.1696/pdf.DOI:10.1002/cmmi.1696.
[67] 朱媛, 段小艺, 王瑞峰, 等.乳腺癌HER2靶向分子探针的制备及体外MRI初步研究[J].中国医学影像学杂志, 2014, 22(5):336-339.DOI:10.3969/j.issn.1005-5185.2014.05.005.Zhu Y, Duan XY, Wang RF, et al.Preparation of HER2-targeted molecular probe and its MR imaging in Vitro[J].Chin J Med Imaging, 2014, 22(5):336-339.
[68] Ding N, Sano K, Kanazaki K, et al.In Vivo HER2-Targeted Magnetic resonance tumor Imaging Using Iron Oxide Nanoparticles Conjugated with Anti-HER2 Fragment Antibody[J/OL].Mol Imaging Biol, 2016[2016-08-03].http://link.springer.com/article/10.1007/s11307-016-0977-2.DOI:10.1007/s11307-016-0977-2.
[69] Yang H, Cai W, Xu L, et al.Nanobubble-Affibody:Novel ultrasound contrast agents for targeted molecular ultrasound imaging of tumor[J].Biomaterials, 2015, 37:279-288.DOI:10.1016/j.biomaterials.2014.10.013.
[70] Dong X, Gu Y.Application of optical molecular imaging technology in the diagnosis and treatment of diseases[J].J Chin Pharm Univ, 2014, 45(2):145-152.DOI:10.11665/j.issn.1000-5048.20140203
[71] Ag D, Bongartz R, Dogan LE, et al.Biofunctional quantum dots as fluorescence probe for cell-specific targeting[J].Colloids Surf B Biointerfaces, 2014, 114:96-103.DOI:10.1016/j.colsurfb.2013.09.033.
[72] Rakovich TY, Mahfoud OK, Mohamed BM, et al.Highly sensitive single domain antibody-quantum dot conjugates for detection of HER2 biomarker in lung and breast cancer cells[J].ACS Nano, 2014, 8(6):5682-5695.DOI:10.1021/nn500212h.
[73] Tu CC, Chen KP, Yang TA, et al.Silicon quantum dot nanoparticles with antifouling coatings for immunostaining on live cancer cells[J].ACS Appl Mater Interfaces, 2016, 8(22):13714-13723.DOI:10.1021/acsami.6b02318.
[74] Michalska M, Florczak A, Dams-Kozlowska H, et al.Peptide-functionalized ZCIS QDs as fluorescent nanoprobe for targeted HER2-positive breast cancer cells imaging[J].Acta Biomater, 2016, 35:293-304.DOI:10.1016/j.actbio.2016.02.002.
[75] Zhao N, Liu S, Jiang Q, et al.Small-protein-stabilized semiconductor nanoprobe for targeted imaging of cancer cells[J].Chembiochem, 2016, 17(13):1202-1206.DOI:10.1002/cbic.201600219.